Seeking Alpha

Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to...

Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to produce and supply its (123) labeled I-drug NAV5001 for late-phase clinical trials. NDZ will manufacture and supply of NAV5001 clinical trial material by radiolabeling NAVB's precursor drug product with Iodine-123 to form (123)I NAV5001, and then manage the logistics and shipping arrangements to third-party clinical trial sites. The agreement could be a precursor to a commercial supply arrangement in the future.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|